retatrutide clinical trials brazil Medscape | The investigational triple GLP-1/GIP/glucagon receptor agonist produced significant weight loss and A1c reduction in people Retatrutide Phase 3: TRIUMPH Program

Phase 3: Thousands of patients are studied to confirm results and compare with current treatments

As of April 2026, neither semaglutide nor tirzepatide appears on the FDA's drug shortage list or 503B bulks list

It is a triple (GLP-1/GIP/Gcg) agonist based on the GLP/GI dual receptor agonist Tirzepatide through a hybrid glucagon (GlucagonGcg) related structure, and is a drug for the treatment of obesity and type 2 diabetes

While some unwanted side effects have come from the method, there have also been some that have been welcomed by users

These benefits have significantly contributed to the growing interest in GLP-1 medications for both diabetes management and weight reduction

Our approach includes: Comprehensive health evaluations before treatment Personalized dosing and ongoing monitoring Nutritional guidance tailored to your needs Recommendations for exercise and wellness support A supportive team to keep you on track By addressing the whole picture, not just the medication, we empower our patients to achieve lasting transformations